Showing 4131-4140 of 9407 results for "".
- Remibrutinib Data at AAAAI Suggests Potential Expansion Beyond CSUhttps://practicaldermatology.com/news/remibrutinib-data-at-aaaai-highlight-expanded-potential-beyond-csu/2485784/New data on the selective Bruton’s tyrosine kinase inhibitor remibrutinib (Rhapsido) is slated for presentation at the 2026 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting, to be held February 27 to March 2 in Philadelphia.
- BE RADIANT: Bimekizumab Delivers Durable Plaque PsO Gains Through 3 Yearshttps://practicaldermatology.com/news/be-radiant-bimekizumab-delivers-durable-pro-gains-through-3-years/2485749/Bimekizumab treatment was associated with rapid and sustained improvements in patient-reported outcomes (PROs) among adults with moderate to seve
- TOGETHER-PsO: Combination Therapy Links Obesity Treatment to Psoriasis Clearancehttps://practicaldermatology.com/news/together-pso-trial-links-obesity-treatment-to-enhanced-psoriasis-clearance/2485716/New data show that a combination therapy of ixekizumab (Taltz) plus tirzepatide (Zepbound) was superior to ixekizumab alone for achieving PASI 100 and ≥10% weight loss at 36 weeks in adults with moderate-to-severe plaque psoriasis. The phase 3b TOGETHER-PsO
- Commentary: Is the IMQ Mouse Model Hindering Psoriasis Research?https://practicaldermatology.com/news/commentary-is-the-imq-mouse-model-hindering-psoriasis-research/2485698/A perspective piece in the Journal of Investigative Dermatology takes a criticial look at the imiquimod (IMQ) mouse model, suggesting its unversality and commonality may be impeding translational progress in psoriasis resea
- Study Details Creation of First Patient Decision Aid for Adult ADhttps://practicaldermatology.com/news/study-details-creation-of-first-patient-decision-aid-for-adult-ad/2485671/A new paper details the development of a patient decision aid (PDA) designed to support shared decision-making for adults with moderate to severe atopic dermatitis (AD), unique in this instance for targeting previously addressed systemic treatment selection for ad
- Study: HS Linked to Hyperglycemia and Altered Amino Acid Metabolism in Plasmahttps://practicaldermatology.com/news/study-hs-linked-to-hyperglycemia-and-altered-amino-acid-metabolism-in-plasma/2485657/New research in the Archives of Dermatological Research shows consistent metabolic alterations in patients with moderate-to-severe hidradenitis suppurativa (HS, particiularly regarding energy and amino acid metabolism, that
- Upadacitinib Shows Rapid, Durable Skin Pain Relief in Moderate-to-Severe Atopic Dermatitishttps://practicaldermatology.com/news/upadacitinib-shows-rapid-durable-skin-pain-relief-in-moderate-to-severe-atopic-dermatitis/2485627/Poster data presented at Winter Clinical Hawaii indicated rapid and sustained reductions in skin pain among adults and adolescents with moderate-to-severe atopic dermatitis (AD) treated with upadacitinib. The analysis emphasized skin pain as a clinically meaningful
- Staphylococcus aureus Implicated as Central Driver of Pediatric Atopic Dermatitishttps://practicaldermatology.com/news/staphylococcus-aureus-implicated-as-central-driver-of-pediatric-atopic-dermatitis/2485614/A comprehensive literature analysis presented at the South Beach Symposium identified Staphylococcus aureus as a key contributor to pediatric atopic dermatitis (AD) pathogenesis, extending beyond disease exacerbation to underlying inflammation and prurit
- Prolactin Receptor Blockade May Promote Hair Growth via Follicular Stem Cell Activationhttps://practicaldermatology.com/news/prolactin-receptor-blockade-may-promote-hair-growth-via-follicular-stem-cell-activation/2485612/Blocking prolactin receptor (PRLR) signaling with the investigational antibody ABS-201 promoted hair follicle growth and stem cell activation in human male scalp skin models, according to preclinical data from Jérémy Chéret, PhD, MSc, at the South Beach Symposium
- Delgocitinib Improves Patient-Reported Outcomes Across Chronic Hand Eczema Subtypeshttps://practicaldermatology.com/news/delgocitinib-improves-patient-reported-outcomes-across-chronic-hand-eczema-subtypes/2485611/Patient-reported outcome (PRO) data from the phase 3 DELTA 1 and DELTA 2 trials suggest that topical delgocitinib cream provides clinically meaningful symptom relief across major subtypes of chronic hand eczema (CHE), according to a poster from Robert Bissonnette,